| Exact Sciences Cor (EXAS) | |||
|---|---|---|---|
| 62.07 1.53 (2.53%) | 05-03 16:00 | ||
| Open: | 62.48 | Pre. Close: | 60.54 |
| High: | 63.99 | Low: | 61.465 |
| Volume: | 1,607,770 | Market Cap: | 11,412(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 83.15 One year: 93.00 |
| Support: | Support1: 57.55 Support2: 47.88 |
| Resistance: | Resistance1: 71.19 Resistance2: 79.62 |
| Pivot: | 61.63  |
| Moving Averages: | MA(5): 60.15  MA(20): 64.40 MA(100): 64.83 MA(250): 72.97 |
| MACD: | MACD(12,26): -1.54 Signal(12,26,9): -1.10 |
| %K %D: | %K(14,3): 22.20 %D(3): 15.77 |
| RSI: | RSI(14): 46.55 |
| 52-Week: | High: 100.77 Low: 56.05 Change(%): -7.8 |
| Average Vol(K): | 3-Month: 2478 10-Days: 1868 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 63.996 - 64.219 | 64.219 - 64.423 |
| Low: | 60.837 - 61.12 | 61.12 - 61.38 |
| Close: | 61.623 - 62.016 | 62.016 - 62.376 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EXAS ] has closed below upper band by 44.7%. Bollinger Bands are 23.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Medical - Diagnostics & Research | |
| Shares Out. (M) | |
| Shares Float (M) | 181.53 |
| % Held by Insiders | 179560000.00 |
| % Held by Institutions | 1.01 |
| Shares Short (K) | 7040 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -102230000.000 |
| Book Value (p.s.) | |
| Profit Margin | -0.76 |
| Operating Margin | -8.17 |
| Return on Assets (ttm) | -11.9 |
| Return on Equity (ttm) | -3.0 |
| Qtrly Rev. Growth | 2500000000.0 |
| Gross Profit (p.s.) | 13.821 |
| Sales Per Share | -5.366 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -1.13 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | 156.12 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | 16.00 |
| Price to Book value | |
| Price to Sales | -11.57 |
| Price to Cash Flow | 4.40 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 6340000.000 |
